[
  {
    "ts": null,
    "headline": "Why Metsera is 'in better hands' with Pfizer than Novo Nordisk",
    "summary": "Pfizer (PFE) has beat out Novo Nordisk (NVO) in the bidding war for obesity medicine company Metsera (MTSR). BMO Capital Markets managing director of biopharma equity research, Evan Seigerman, discusses why he thinks the acquisition worked out in the best way for all parties. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=4e0cbad295ef9c650787e68ec582e8ebff0e0076b0788571e30a2ca2af8c8a5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762889400,
      "headline": "Why Metsera is 'in better hands' with Pfizer than Novo Nordisk",
      "id": 137449943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has beat out Novo Nordisk (NVO) in the bidding war for obesity medicine company Metsera (MTSR). BMO Capital Markets managing director of biopharma equity research, Evan Seigerman, discusses why he thinks the acquisition worked out in the best way for all parties. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=4e0cbad295ef9c650787e68ec582e8ebff0e0076b0788571e30a2ca2af8c8a5b"
    }
  },
  {
    "ts": null,
    "headline": "Markets exhale as Novo Nordisk withdraws from Metsera bidding war",
    "summary": "Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.View on euronews",
    "url": "https://finnhub.io/api/news?id=ca7c0cf51c85f7f87e3e4fcd546cacf88c001045b4b041b33a5ba93452fbf54b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762878622,
      "headline": "Markets exhale as Novo Nordisk withdraws from Metsera bidding war",
      "id": 137448925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.View on euronews",
      "url": "https://finnhub.io/api/news?id=ca7c0cf51c85f7f87e3e4fcd546cacf88c001045b4b041b33a5ba93452fbf54b"
    }
  },
  {
    "ts": null,
    "headline": "5 Highest Yielding Dividend Stocks in the S&P 500",
    "summary": "The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants. The S&P 500 is packed with the biggest and the best companies, celebrated for the price swings, cash flow, and high upside potential. The index is massive and is often associated ... 5 Highest Yielding Dividend Stocks in the S&P 500",
    "url": "https://finnhub.io/api/news?id=e873a0b00ea8dabe222a7cb7b0fff0b1eb0fdb41e27714edba146a01e78d52a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762876404,
      "headline": "5 Highest Yielding Dividend Stocks in the S&P 500",
      "id": 137448926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants. The S&P 500 is packed with the biggest and the best companies, celebrated for the price swings, cash flow, and high upside potential. The index is massive and is often associated ... 5 Highest Yielding Dividend Stocks in the S&P 500",
      "url": "https://finnhub.io/api/news?id=e873a0b00ea8dabe222a7cb7b0fff0b1eb0fdb41e27714edba146a01e78d52a5"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Pfizer Be in 3 Years?",
    "summary": "Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.",
    "url": "https://finnhub.io/api/news?id=4e2fd35e53c167e69bdf927e2292a4dbfa1f60ac563dce3b54e59831b674eea1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762873620,
      "headline": "Where Will Pfizer Be in 3 Years?",
      "id": 137448927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.",
      "url": "https://finnhub.io/api/news?id=4e2fd35e53c167e69bdf927e2292a4dbfa1f60ac563dce3b54e59831b674eea1"
    }
  },
  {
    "ts": null,
    "headline": "Alpha-1 Antitrypsin Deficiency Disease Market Research Report 2025, Competitive Analysis of Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, Pfizer, Baxter",
    "summary": "The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Alpha-1 Antitrypsin Defic",
    "url": "https://finnhub.io/api/news?id=9480cbbc44564dcad66f981b0ee2cd5a4e058cc202b89e4878abaad03cb0d135",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762872300,
      "headline": "Alpha-1 Antitrypsin Deficiency Disease Market Research Report 2025, Competitive Analysis of Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, Pfizer, Baxter",
      "id": 137448928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Alpha-1 Antitrypsin Defic",
      "url": "https://finnhub.io/api/news?id=9480cbbc44564dcad66f981b0ee2cd5a4e058cc202b89e4878abaad03cb0d135"
    }
  },
  {
    "ts": null,
    "headline": "Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio",
    "summary": "The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Sickle Cell Disease Treatmen",
    "url": "https://finnhub.io/api/news?id=c109a8f6c4a8587dcd3f4daebe577b3efbb7abe1d07c6d2d6a0a779e857a19c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762872000,
      "headline": "Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio",
      "id": 137448929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Sickle Cell Disease Treatmen",
      "url": "https://finnhub.io/api/news?id=c109a8f6c4a8587dcd3f4daebe577b3efbb7abe1d07c6d2d6a0a779e857a19c3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's (NYSE:PFE) Solid Earnings Are Supported By Other Strong Factors",
    "summary": "Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...",
    "url": "https://finnhub.io/api/news?id=a52bedb044df45f30b34939e671ad9534078a0772221d38fc6ee228714a8f507",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762858720,
      "headline": "Pfizer's (NYSE:PFE) Solid Earnings Are Supported By Other Strong Factors",
      "id": 137448930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...",
      "url": "https://finnhub.io/api/news?id=a52bedb044df45f30b34939e671ad9534078a0772221d38fc6ee228714a8f507"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drugs Are About to Go Mass-Market",
    "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
    "url": "https://finnhub.io/api/news?id=229a408931ff92dcb9dcee7ea1027d0413a16f2ffee778ccc7af5a424f69a726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762857000,
      "headline": "Obesity Drugs Are About to Go Mass-Market",
      "id": 137448682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
      "url": "https://finnhub.io/api/news?id=229a408931ff92dcb9dcee7ea1027d0413a16f2ffee778ccc7af5a424f69a726"
    }
  },
  {
    "ts": null,
    "headline": "Vaccines Market Research and Forecast Report 2025-2030: Growing Focus on Vaccine Development, New Product Launches, and Large-scale Immunization Programs Continues to Accelerate Growth",
    "summary": "The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ",
    "url": "https://finnhub.io/api/news?id=406154e92c5ebedf94ffd0c94c76500836106d1895ded014e52b4c75a06e68bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762856940,
      "headline": "Vaccines Market Research and Forecast Report 2025-2030: Growing Focus on Vaccine Development, New Product Launches, and Large-scale Immunization Programs Continues to Accelerate Growth",
      "id": 137448932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ",
      "url": "https://finnhub.io/api/news?id=406154e92c5ebedf94ffd0c94c76500836106d1895ded014e52b4c75a06e68bd"
    }
  },
  {
    "ts": null,
    "headline": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
    "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
    "url": "https://finnhub.io/api/news?id=8be5d90efd7888e4bff1290cefd3c2c7d5ddd3f2c2a4db44726bdb42c8c800e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762853100,
      "headline": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
      "id": 137448683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
      "url": "https://finnhub.io/api/news?id=8be5d90efd7888e4bff1290cefd3c2c7d5ddd3f2c2a4db44726bdb42c8c800e5"
    }
  },
  {
    "ts": null,
    "headline": "Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring",
    "summary": "Pfizer not only beat expectations last quarter, but also boosted its guidance.",
    "url": "https://finnhub.io/api/news?id=16dec4b0139a99ed9a8cb588f83f7fef337ec520178bfdf846a32b34a9cd64cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762852200,
      "headline": "Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring",
      "id": 137448934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer not only beat expectations last quarter, but also boosted its guidance.",
      "url": "https://finnhub.io/api/news?id=16dec4b0139a99ed9a8cb588f83f7fef337ec520178bfdf846a32b34a9cd64cc"
    }
  },
  {
    "ts": null,
    "headline": "Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer",
    "summary": "Pfizer acquires Metsera, gaining cutting-edge obesity and diabetes therapies.",
    "url": "https://finnhub.io/api/news?id=10e3943d5b4f81551f61d14a7a5ab3c21765477e6963e86d795b7c12a884b238",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762846610,
      "headline": "Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer",
      "id": 137447108,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306680389/image_1306680389.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer acquires Metsera, gaining cutting-edge obesity and diabetes therapies.",
      "url": "https://finnhub.io/api/news?id=10e3943d5b4f81551f61d14a7a5ab3c21765477e6963e86d795b7c12a884b238"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call",
    "summary": "Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod",
    "url": "https://finnhub.io/api/news?id=5dc49951bccaf5b3a5694d017c626d97081353e5054a2e73b1e23f215fd70331",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762839377,
      "headline": "The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call",
      "id": 137448935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod",
      "url": "https://finnhub.io/api/news?id=5dc49951bccaf5b3a5694d017c626d97081353e5054a2e73b1e23f215fd70331"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript",
    "summary": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM ESTCompany...",
    "url": "https://finnhub.io/api/news?id=06584777625c42eb7c43add491202728a4f954af977d66769b1636bb12300aa2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762831896,
      "headline": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript",
      "id": 137438758,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM ESTCompany...",
      "url": "https://finnhub.io/api/news?id=06584777625c42eb7c43add491202728a4f954af977d66769b1636bb12300aa2"
    }
  }
]